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Introduction
The goals of the workshop, convened from March 5 to 
7,1994, were to bring together experts from Europe and 
North America to address the current situation with re­
gard to the early detection of prostate cancer. The topics 
discussed included assessment of the epidemiology of 
this condition on a global basis, the accuracy of clinical 
diagnosis, the pathologic evaluation, the available lab­
oratory tests, the methodology of detection and screen­
ing programs, and results and treatment. A workshop 
summary from each group was provided at the meeting, 
and adaptations of these are contained in this report. 
Providing answers to the following questions was the 
meeting's major goal.
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1. Is there an acceptable method for early detection of 
prostate cancer available on a population basis?
2. Do the current results provide encouragement for 
proceeding to develop widespread, randomized tri­
als?
3. What is the proper way to conduct such efforts and 
what other important issues should be considered?
4. What are the bases for the treatment of patients 
with prostate cancer when discovered?
These issues are addressed in a comprehensive 
fashion below.
EPIDEMIOLOGY WORKGROUP
In many countries of the world, prostate cancer is the 
second most common form of cancer in men and in the 
United States it has recently overtaken lung cancer in 
terms of absolute incidence, although it remains second 
to lung cancer as a cause of death. Given that in several 
countries, a higher number of children born after 1945 
will be in their mid-fifties in the early part of the 21st 
century (at which age cancer risk becomes an important 
consideration), coupled with the trend toward in­
creased life expectancy, there will be an increase in the 
numbers of patients diagnosed with prostate cancer 
even if incidence rates remain fixed at 1980 levels. In 
the absence of treatment improvements, and with pros­
pects for prevention by lifestyle modification only a re­
mote hope in the current circumstances, it seems that 
there will also be an increase in the number of deaths 
from prostate cancer worldwide.
The situation could be further augmented by the 
presence of temporal trend toward increased risk of 
prostate cancer that is consistently reported in many
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countries and that is unlikely to be entirely artifact. 
However, in many countries there has been little 
change in the mortality rate for prostate cancer, partic­
ularly at younger (< 70 years) ages since 1950 (Boyle P, 
Evstifeeva T, Maisonneuve P, Macfarlane EJ, Pagano F, 
unpublished data).
A major effort is required to reduce the impact of 
these changes and reduction of mortality by population 
screening has emerged as one possible way to accom­
plish this.1 In this context, screening involves the exam­
ination of asymptomatic men to classify them as likely 
or unlikely to have prostate cancer. Men who appear 
likely to have the disease are investigated further to ar­
rive at a final diagnosis and those who are found to have 
the disease are treated. Screening calls attention to the 
likelihood of disease before symptoms appear. The goal 
of a screening program is to reduce mortality from the 
disease among those screened by treatment of disease 
before symptoms appear. There have been criteria es­
tablished to determine whether a screening activity 
could be justified in a particular circumstance2 and at 
the present time, these criteria are almost completely 
fulfilled for prostate cancer.3 The notable exceptions are 
the lack of detailed knowledge of the natural history of 
prostate cancer and lack of direct evidence that screen­
ing with the currently available modalities can lead to a 
reduction in prostate cancer mortality.
Although population screening for prostate cancer 
cannot be recommended as public health policy at the 
present time, there are strong arguments supporting the 
conduct of trials of screening (see Appendix 1 for this 
and other recommendations of this workgroup). It is 
recognized that possibilities for the conduct of such ran­
domized trials are favorable in Europe at the present 
time. Such randomized trials need to be large and of 
long duration. They will be more complicated than trials 
of mammography and breast cancer screening as a re­
sult of several factors, including the nature of prostate 
cancer. In particular, there is a need to have reliable in­
formation about patterns of cancer care and treatment 
of prostate cancer in the study region, Men in an age 
group that is not treated according to local policy (older 
than 70 years of age in some areas) should not be re­
cruited into screening trials as they are very unlikely to 
benefit from participation. Information is required 
about patterns of care in the study region. Patterns of 
health care for men enrolled in screening trials should 
be as similar as possible in both the screened and the 
unscreened group members. Cancer registries in the 
study region have an important role in identifying any 
interval cancers arising in the study participants, some 
of which may be missed, and in providing a backup to 
existing follow-up procedures. Cancer registries also 
provide an important resource of information regarding
background incidence, mortality, and survival rates and 
follow-up for men who either refuse to participate in 
the trial or drop out during the study.
Care is required when dealing with aspects of the 
diagnosis of prostate cancer. A potential problem in­
volves autopsy diagnosis, but this is only a relevant 
finding when it identifies the prostate as the primary 
site in the case of a man who died of metastatic disease 
whose primary origin was unknown (or wrongly attrib­
uted to another site) in life (occult cancer). In each trial, 
a committee should be established to determine 
whether prostate cancer was the underlying cause of 
death in study participants. Although death certificates 
appear to be reasonably reliable, there is need for de­
tailed examination of each cause of death by clinicians 
who are expert in the disease in question. The need for 
large trials argues strongly for multicentred studies that 
probably will need to be conducted in international 
populations. Careful scrutiny of the reproducibility of 
the determination of prostate cancer as underlying 
cause of death in different countries is needed.
Screening trials require careful planning to ensure 
that the data can be used correctly for evaluation. The 
most reliable evaluation of screening activities is 
through the correct analysis of the randomized clinical 
trial data. However, modeling strategies have also 
proved useful and have a role in helping choose be­
tween the utility of different screening procedures.4 The 
list of data required from a screening trial to allow eval­
uation is contained in Appendix 2.
As stated above, the goal of screening is to decrease 
the death rate from prostate cancer. Using death as the 
principle endpoint minimizes many possible biases and 
requires 10-20 years to complete. Regardless of the 
screening tests employed, the present climate of tech­
nologic advances offers the option of obtaining inter­
mediate results in a shortened time by using prognostic 
indicators of death from prostate cancer. A decrease in 
the incidence rate of advanced cancer is the best inter­
mediate indicator of a ultimate reduction in mortality. 
The use of intermediate endpoints at this time must be 
informal because they themselves require validation by 
mortality data from screening trials;5 valid intermediate 
endpoints classify tumors into a number of categories 
within which survival is independent of mode of detec­
tion.
Using data from the Surveillance, Epidemiology, 
and End Results Program, available prognostic death 
indicators were ranked by their death potential with 7 
to 18 years of follow-up. Gleason grade was found to 
be a strong indicator of the virulence of cancers in all 
stages and should also attempt to be gathered on all 
cancers.6 There should be a uniform method of record­
ing staging information on prostate cancer that is used
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in all countries and can be compared through time 
(TNM is the most widely used scheme internationally).
Quality of life is a major issue, particularly when 
considering disease in older men. The criteria estab­
lished by Wilson and Jungner, however, lack any crite­
rion about quality of life. It is recommended that two 
important aspects of quality of life be measured in study 
participants: general quality of life and quality of uro- 
logic life, the latter, for example, including urinary 
symptomatology, annoyance of symptoms, interfer­
ence with daily living, and sexual function. Quality of 
life assessment should be performed both for men free 
from prostate cancer and men with the disease in the 
screened and control groups. The measurements should 
be made at several stages of the disease course and also 
during eventual life-years gained. Much basic research 
work remains to be performed in this field before vali­
dated instruments will be available for use.
In conducting large scale screening trials, it is im­
portant to maximize the utility of this resource, for ex­
ample by conducting etiologic studies within this as­
sembled cohort. The establishment of a biologic data 
bank would maximize the value of this resource and 
help provide answers to several important research 
questions about prostate cancer that are complementary 
to the main question addressed by screening trials.
The potential list of data items is extremely long; 
this list represents the minimum data required for a 
thorough examination of the findings from screening 
trials.
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Appendix 1 
Recommendations of the Epidemiologic Group 
on Prostate Cancer Screening
Widespread population screening for prostate cancer 
cannot be recommended as public health policy at
the present time. Demonstration projects have pro­
vided valuable data and have assisted public edu­
cation, providing very strong arguments in support 
of conducting randomized trials for screening.
Eligible men should have a life expectancy compatible 
with the expected duration of the study; and men 
to whom no curative treatment is given (in several 
countries, men older than 70 years of age) should 
not be eligible to participate in screening trials.
Patterns of health care for men enrolled in screening 
trials should be as similar as possible in both the 
screened and the unscreened group.
Comparable staging and diagnostic systems for prostate 
cancer should be used (e.g., TNM).
Information about patterns of care in the study regions 
should be available.
Incorporation of quality-of-life measurement in both 
screened and unscreened groups in randomized tri­
als should be made, These should refer to both 
overall quality of life and to urologic quality of life 
specifically.
The opportunity offered by screening trials to conduct 
etiologic research should be noted.
Biologic material should be obtained and stored when­
ever possible for future analysis (of new markers 
for etiologic studies, etc.).
There should be a liaison between study coordinators 
and cancer tumor registries that is active in the re­
gion where screening trials are being conducted.
The principal method of evaluating screening trials is a 
correct statistical analysis of randomized trial data, 
but modeling is also of importance to help in the 
comparison of the utility and cost-effectiveness of 
different screening strategies.
Each study requires the establishment of a committee to 
evaluate the cause of death of study participants. 
There is a need for more research about the compa­
rability of cause of death abstraction in different 
countries.
Using death from prostate cancer as the principle end­
point in screening trials minimizes several possible 
biases but requires 10 to 20 years to complete. In­
termediate results could be obtained by using prog­
nostic indicators of death from prostate cancer (e.g., 
grading, stage, etc.).
Appendix 2 
Minimal Information Required for Evaluation of 
Cancer Screening Trials
Target population
Invited population
Attendance
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Nonparticipant characteristics 
Screen-positive
Additional diagnostic tests (and results)
Additional invasive diagnostic tests 
Lost to follow-up/assessment unknown 
Cancers detected (by test)
Stages and other prognostic factors (T /N /M /grade / 
etc.)
Primary treatment of screen-detected cancers 
Advanced disease in follow-up period (Ml, regional re­
currences)
Cancers diagnosed after negative screen 
Deaths from other diseases
Similar detailed information on control group (diagnos­
tic tests/screen tests/treatment/etc.)
Quality of life measurements 
Cost measurements
Cost measurement analysis (screening/diagnosis and 
therapeutic phases)
Participants
Anssi Auvinen, M.D. (Co-Chair), Senior Scientist, Fin­
nish Cancer Registry, Institute for Statistical and Epide­
miological Cancer Research, Helsinki, Finland; Peter 
Boyle, M.D. (Chair), Director, Division of Epidemiology
& Biostatistics, European Institute of Oncology, Milano, 
Italy; R.A.M. Damhuis, M.D., Integraal kankercentrum 
Rotterdam, Rotterdam, the Netherlands; H.J. de Kon- 
ing, M.D., Department of Public Health, Erasmus Uni­
versity Rotterdam, Rotterdam, the Netherlands; Mi­
chael Garraway, M.D., Department of Public Health 
Sciences, University of Edinburgh Medical School, Ed­
inburgh, United Kingdom; Margaret Haelterman, M.D., 
National Cancer Registry, Belgisch Werk tegen Kanker, 
Brussels, Belgium; Charles Smart, M.D. (Co-Chair), Salt 
Lake City, Utah; Joost Weyler, M.D., Departement Gen­
eeskunde, Epidemiologie & Sociale Geneeskunde, Uni­
versitaire Instelling Antwerpen, Antwerp, Belgium.
PATHOLOGY WORKGROUP
The Pathology Working Group (PWG) recognizes that 
screening programs have the authority and responsibil­
ity to specify conditions of quality control and quality 
assurance within the screening facility. However, once 
an abnormality is detected, the follow-up facilities for 
surgical excision and pathologic examination are not 
necessarily a part of the screening facility. Therefore, 
the PWG's objective was to develop criteria for the ex­
amination of prostate tissue specimens that would be 
generally acceptable to practicing surgical pathologists 
for the formulation of their consultation reports. The
information included below is directed primarily to the 
consultative practice of pathology and is not specifically 
for research. Nevertheless, this information may be 
used in a clinical trial setting, and can be modified as 
appropriate for use in a specific protocol or institution. 
In this context, the participants of the PWG have for­
mulated the following recommendations for the exami­
nation and surgical pathology consultation reports of 
prostate cancer specimens to document the extent of tis­
sue removed, validate the diagnosis of cancer in the 
specimen (or its absence), and provide information that 
may be used for International Union Against Cancer/ 
American Joint Committee on Cancer pTNM classifi­
cation and staging, selection of therapy, and estimation 
of prognosis, The PWG therefore has included much of 
the data that have already been developed and reality 
tested by the Cancer Committee of the College of Amer­
ican Pathologists,1
The PWG made some general observations during 
the development of these recommendations. They 
unanimously agreed that prostate carcinomas should be 
assigned a histologic grade, and preferred a three-grade 
system; however, they also concurred that the grading 
system employed by a pathologist should be deter­
mined by her/his local medical practice environment. 
Therefore, the PWG include the following in the rec­
ommendation for histologic grading: "Any grading sys­
tem as desired, such as Gleason's score"1 (see below). 
Of course, the grading system used should include a 
verbal definition in the report such as . .moderately 
differentiated, grade 2."
The surgical pathology consultation report of a 
prostate specimen should include a statement confirm­
ing the presence (or absence) of carcinoma, or that it 
may not be possible to make a definitive diagnostic 
evaluation for carcinoma and state the reason (e.g., pos­
sibly due to limitations of the specimen). Prostate can­
cer associated lesions, such as prostatic intraepithelial 
neoplasia (PIN), atypical adenomatous hyperplasia 
(AAH), and the effects of therapy, may also be included. 
The PWG recommends that a group of pathologists de­
velop a lexicon of definitions of terms, with appropriate 
related photomicrographs, to assist pathologists in the 
uniform application of the terminology specified in this 
report.
Recommendations follow for the information to be 
included in the surgical pathology consultation reports 
for four categories of specimens (1) needle biopsy, (2) 
transurethral resection of prostate (TURP), (3) supra­
pubic or retropubic prostate enucleation (subtotal pros­
tatectomy), and (4) radical prostatectomy. Although 
prostate carcinoma can be diagnosed by fine needle as­
piration cytology of the prostate gland with or without 
DNA analysis by flow cytometry or nuclear morphome­
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try, this report is limited to solid tissue examination. 
There is repetition of information in the four categories 
of specimens because many of the data are common for 
all types of specimens; this deliberate repetition is in­
tended for the convenience of the reader and for those 
who may wish to duplicate this material for use in their 
laboratory.
We cannot emphasize too strongly how important 
it is to provide basic clinical data to the pathologist for 
appropriate patient identification and clinical-patho­
logic correlation.
Recommendations for Data to be Included in the 
Surgical Pathology Consultation Report for the 
Four Types of Specimens
1. Needle biopsy
1.1 Clinical information provided to pathologist by 
the responsible physician
1.1.1 Patient identification (name/age/identifies- 
tion number)
1.1.2 Relevant history, including any previous di­
agnosis /  therapy
1.1.3 Results of examinations
1.1.3.1 Laboratory (e.g., PSA or other significant 
findings)
1.1.3.2 Digital rectal examina tion
1.1.3.3 Imaging (e.g., ultrasound)
1.1.4 Clinical diagnosis
1.1.5 Type of surgical procedure (e.g., needle bi~ 
opsy)
1.1.6 Anatomic site of specimen [site(s) of biopsy 
specified by surgeon, as appropriate]
1.1.6.1 Location in prostate gland [right or left 
lobe; base, mid, apex (as labeled by surgeon)]
1.1.6.2 Extraprostatic site(s) (e.g., right/left semi­
nal vesicle(s), as labeled by surgeon)
1.2 Macroscopic examination (size/number of 
pieces)
1*3 Microscopic examination
1.3.1 Tumor characteristics
1.3.1.1 Histologic type (World Health Organiza­
tion modified)
1.3.1.1.1 Adenocarcinoma (not otherwise speci­
fied)
1.3.1.1.2 Acinar adenocarcinoma
1.3.1.1.3 Ductal adenocarcinoma
1.3.1.1.4 Mucinous adenocarcinoma
1.3.1.1.5 Transitional cell carcinoma
1.3.1.1.6 Squamous cell carcinoma
1.3.1.1.7 Neuroendocrine tumor
1.3.1.1.8 Small cell anaplastic carcinoma
1.3.1.1.9 Undifferentiated carcinoma
1.3.1.1.10 Other cancer (specify)
1.3.1.2 Histologic grade of tumor (any grading sys­
tem as desired, such as Gleason's histologic score; spec­
ify grading system used)
1.3.1.3 Extent of tumor
1.3.1.3.1 Proportion (%) of tissue involved
1.3.1.3.2 Lymphatic vessel invasion
1.3.1.3.3 Blood vessel invasion
1.3.1.3.4 Perineural invasion
1.3.1.3.5 Periprostatic tissue invasion (if appropri­
ate)
1.3.1.3.6 Adjacent organs(s): specify
1,3.1.4 International Union Against Cancer 
(UICC)/American Joint Committee on Cancer (AJCC) 
pT category
1.3.2 Malignancy indeterminate (specify nature of 
the problem)
1.3.3 No tumor identified (if the tissue is not ade­
quate for diagnostic evaluation for tumor, this should 
be noted)
1.3.4 Other findings, as appropriate
1.3.4.1 Prostatic intraepithelial neoplasia (PIN), 
and grade
1.3.4.2 Atypical adenomatous hyperplasia (AAH)
1.3.4.3 Prostatitis (granulomatous or other)
1.3.4.4 Benign prostatic hyperplasia
1.3.4.5 Basal cell hyperplasia
1.3.4.6 Postatrophy hyperplasia
1.3.4.7 Therapy related
1.4 Special studies [if special studies have been 
performed, they should be designated and the results 
included with the surgical pathology consultation re­
port (e.g., histochemistry, immunohistochemistry, flow 
cytometry, or nuclear morphometry)].
2. Transurethral resection of prostate (TURP)
2.1 Clinical information provided to pathologist by 
the responsible physician
2.1.1 Patient identification (nam e/age/identifica­
tion number)
2.1.2 Relevant history, including any previous di­
agnosis/therapy
2.1.3 Results of examinations
2.1.3.1 Laboratory (e.g., PSA or other significant 
findings)
2.1.3.2 Digital rectal examination
2.1.3.3 Imaging (e.g., ultrasound)
2.1.4 Clinical diagnosis
2.1.5 Type of surgical procedure (e.g., TURP)
2.1.6 Anatomic site of specimen (prostate gland)
2.2 Macroscopic examination
2.2.1 General characteristics of specimen
2.2.1.1 Weight
2.2.1.2 Significant gross features
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2.2.2 Recommendations for selection of tissue for 
microscopic examination
2.2.2.1 Include any grossly suspicious chips
2.2.2.2 Specimens < 12  grams, embed totally
2.2.2.3 Specimens > 12 grams, embed at least 12 
grams and approximately 1 additional cassette for every
10 grams
2.2.3 After diagnosis of a clinically unsuspected 
(incidental) carcinoma that involves 5% or less of the 
tissue, or high grade PIN, or atypical adenomatous hy­
perplasia, consider embedding (all) remaining tissue.
2.3 Microscopic examination
2.3.1 Tumor characteristics
2.3.1.1 Histologic type (World Health Organiza­
tion modified)
2.3.1.1.1 Adenocarcinoma (not otherwise speci­
fied)
2.3.1.1.1 Acinar adenocarcinoma
2.3.1.1.2 Ductal adenocarcinoma
2.3.1.1.3 Mucinous adenocarcinoma
2.3.1.1.4 Transitional cell carcinoma
2.3.1.1.5 Squamous cell carcinoma
2.3.1.1.6 N euro endocrine tumor
2.3.1.1.7 Small cell anaplastic carcinoma
2.3.1.1.8 Undifferentiated carcinoma
2.3.1.1.9 Other cancer (specify)
2.3.1.2 Histologic Grade of Tumor (any grading 
system as desired such as Gleason's histologic score; 
specify grading system used)
2.3.1.3 Extent of tumor
2.3.1.3.1 Proportion (%) of tissue involved
2.3.1.3.2 Lymphatic vessel invasion
2.3.1.3.3 Blood vessel invasion
2.3.1.3.4 Perineural invasion
2.3.1.3.5 Periprostatic tissue invasion (if appropri­
ate)
2.3.1.3.6 Direct extension to adjacent organs(s): 
specify
2.3.1.4 UICC/AJCCpT Category
2.3.2 Malignancy Indeterminate (specify nature of 
the problem)
2.3.3 No tumor identified (if the tissue is not ade­
quate for diagnostic evaluation for tumor, this should 
be noted).
2.3.4 Other findings, as appropriate
2.3.4.1 PIN and grade
2.3.4.2 AAH
2.3.4.3 Prostatitis (granulomatous or other)
2.3.4.4 Benign prostatic hyperplasia
2.3.4.5 Basal cell hyperplasia
2.3.4.6 Posta trophy hyperplasia
2.3.4.7 Therapy related
2.4 Special studies [Designate special studies, if 
done, and include results with Surgical Pathology Con­
sultation Report (e.g., histochemistry, immunohisto- 
chemistry, flow cytometry, nuclear morphometry)].
3. Suprapubic or retropubic enucleation specimen 
(subtotal prostatectomy)
3.1 Clinical information provided to pathologist by 
the responsible physician
3.1.1 Patient identification (name/age/identifica-
tion number)
3.1.2 Relevant history, including any previous di­
agnosis/therapy
3.1.3 Results of Examinations
3.1.3.1 Laboratory (e.g., PSA or other significant 
findings)
3.1.3.2 Digital rectal examination
3.1.3.3 Imaging (e.g., ultrasound)
3.1.4 Clinical diagnosis
3.1.5 Type of surgical procedure (e.g., subtotal 
prostatectomy)
3.1.6 Anatomic site of specimen (prostate gland)
3.1.7 Orientation of the specimen as marked by the 
surgeon (e.g., area of possible invasion of margin)
3.2 Macroscopic examination
3.2.1 General characteristics of prostate specimen
3.2.1.1 Size, three dimensions
3.2.1.2 Weight
3.2.1.3 Size of carcinoma(s), if possible
3.2.1.4 Other significant gross features
3.2.1 Method of margin identification (e.g., india
ink)
3.2.2 Recommendations for selection of tissue for 
microscopic examination
3.2.2.1 Approximately eight cassettes including:
3.2.2.1.1 Any areas suspicious for tumor, noting 
location (right, left lobe, etc.)
3.2.2.1.2 Extent, if possible
3.2.2.1.3 Other representative sections as appro­
priate
3.2.2.2 Additional sections may be needed for fur­
ther evaluation after diagnosis of a neoplasm to evalu­
ate tumor characteristics (see Microscopic features, be­
low)
3.3 Microscopic examination
3.3.1 Tumor characteristics
3.3.1.1 Histologic Type (World Health Organiza­
tion modified)
3.3.1.1.1 Adenocarcinoma (not otherwise speci­
fied)
3.3.1.1.2 Acinar adenocarcinoma
3.3.1.1.3 Ductal adenocarcinoma
3.3.1.1.4 Mucinous adenocarcinoma
3.3.1.1.5 Transitional cell carcinoma
3.3.1.1.6 Squamous cell carcinoma
3.3.1.1.7 N euroendocrine tumor
3.3.1.1.8 Small cell anaplastic carcinoma
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3.3.1.1.9 Undifferentiated carcinoma
3.3.1.1.10 Other cancer (specify)
3.3.1.2 Histologic Grade of Tumor (any grading 
system as desired, such as Gleason's histologic score; 
specify grading system used)
3.3.1.3 Extent of tumor
3.3.1.3.1 Distribution of tumor in the specimen 
(e.g. right lobe, left lobe)
3.3.1.3.2 Quantitation of tumor (determine from 
gross and/or microscopic findings)
3.3.1.3.3 Lymphatic vessel invasion
3.3.1.3.4 Blood vessel invasion
3.3.1.3.5 Perineural invasion
3.3.1.3.6 Periprostatic tissue invasion (if appropri­
ate)
3.3.1.3.7 Direct extension to adjacent organs(s): 
specify
3.3.1.4 Status of margins, if possible
3.3.1.5 UICC/AJCC pT Category
3.3.2 Malignancy indeterminate (specify nature of 
the problem)
3.3.3 No Tumor Identified
3.3.4 Other findings, as appropriate
3.3.4.1 PIN and grade
3.3.4.2 AAH
3.3.4.3 Prostatitis (granulomatous or other)
3.3.4.4 Benign prostatic hyperplasia
3.3.4.5 Basal cell hyperplasia
3.3.4.6 Postatrophy hyperplasia
3.3.4.7 Therapy related
3.4 Special studies designate special studies, if 
done, and include results with surgical pathology con- 
sultation report (e.g., histochemistry, immunohisto- 
chemistry, flow cytometry, nuclear morphometry)].
4. Radical prostatectomy
4.1 Clinical information provided to pathologist by 
the responsible physician
4.1.1 Patient identification (name/age/identifica- 
tion number)
4.1.2 Relevant history, including any previous di­
agnosis/therapy
4.1.3 Results of examinations
4.1.3.1 Laboratory (e.g., PSA or other significant 
findings)
4.1.3.2 Digital rectal examination
4.1.3.3 Imaging (e.g., ultrasound)
4.1.4 Clinical diagnosis
4.1.5 Type of surgical procedure (specified by 
surgeon)
4.1.5.1 Perineal prostatectomy
4.1.5.2 Retropubic prostatectomy
4.1.5.3 Nerve-sparing prostatectomy (left/right/ 
both)
4.1.5.4 Standard radical prostatectomy
4.1.5.5 Super-ra dical prostatectomy
4.1.6 Anatomic site of specimen:
4.1.6.1 Prostate gland
4.1.6.2 Regional lymph nodes (site and laterality 
specified by surgeon)
4.1.7 Orientation of the specimen as marked by the 
surgeon (e.g., area of possible invasion of margin)
4.2 Macroscopic examination
4.2.1 Prostatectomy
4.2.1.1 Structures included should be noted
4.2.1.1.1 Prostate
4.2.1.1.2 S eminal vesicles
4.2.1.1.3 Segments of vasa deferentia
4.2.1.1.4 All or portion of bladder
4.2.1.1.5 Other (specify)
4.2.1,2 Description of type of prostate specimen
4.2.1.2.1 Total
4.2.1.2.2 Subtotal prostate
4.2.1.2.3 Size, three dimensions
4.2.1.2.4 Weight
4.2.1.2.5 Size of carcinoma(s), if possible
4.2.1.2.6 Method of margin identification (e.g., In­
dia ink)
4,2.2 Regional (pelvic) lymph nodes
4.2.2.1 Site and laterality (as specified by surgeon)
4.2.2.2 Number
4.2.2.3 Location
4.2.2.4 Size of largest gross metastasis
4.2,3 Recommendations for selection of tissues for 
microscopic examination
4.2.3.1 Tumor (each grossly recognizable tumor)
4.2.3.1.1 Location (right, left lobe, etc.), and extent
4.2.3.1.2 Extent, if possible
4.2.3.2 Sections to determine extent of invasion 
and margins
4.2.3.2.1 Apex (urethral) margin
4.2.3.2.2 Base (bladder neck) margin
4.2.3.2.3 Prostatic "'capsule"
4.2.3.2.4 Circumferential periprostatic margins ad­
jacent to tumor, including neurovascular bundle, as ap­
propriate.
4.2.3.2.5 Seminal vesicles
4.2.3.2.6 Periprostatic tissue about the bases of 
seminal vesicles
4.2.3.2.7 Additional sections to determine multi­
centricity
4.2.3.3 All lymph nodes (specify laterality and site 
as specified by surgeon)
4.3 Microscopic examination
4.3.1 Tumor characteristics
4.3.1.1 Histologic type (World Health Organiza­
tion modified)
4.3.1.1.1 Adenocarcinoma (not otherwise speci­
fied)
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4.3.1.1.2 Acinar adenocarcinoma
4.3.1.1.3 Ductal adenocarcinoma
4.3.1.1.'4 Mucinous adenocarcinoma
4.3.1.1.5 Transitional cell carcinoma
4.3.1.1.6 Squamous cell carcinoma
4.3.1.1.7 Neuroendocrine tumor
4.3.1.1.8 Small cell anaplastic carcinoma
4.3.1.1.9 Undifferentiated carcinoma
4.3.1.1.10 Other cancer (specify)
4.3.1.2 Histologic grade of tumor (any grading sys­
tem as desired, such as Gleason's histologic score; spec­
ify grading system used)
4.3.1.3 Extent of tumor
4.3.1.3.1 Distribution of tumor in the specimen 
(e.g., right lobe, left lobe)
Participants
Fernando Algaba, M.D., (Co-Chair), Section of Pathol­
ogy, Fundacion Puigvert, Barcelona, Spain; H. Bonk- 
hoff, M.D., Pathologisches Institut, Universität des 
Saarlandes, Hombourg/Saar Deutchland; J. Bultinck, 
M.D,, Department of Pathology, A.Z. Middelheim, 
Antwerp, Belgium; Robert V.P. Hutter, M.D. (Chair), 
Chairman, Department of Pathology, St. Barnabas 
Medical Center, Livingston, New Jersey; Curtis A. Pet- 
taway, M.D., Department of Urology, M.D. Anderson 
Cancer Center, Houston, Texas; Theodorus H. van der 
Kwast, M.D. (Co-Chair), Department of Pathology, 
Erasmus University Rotterdam, Rotterdam, the Nether­
lands; Eric van Marek, M.D., Department of Pathology,
4.3.'1.3.2 Quantitation of tumor (determine from University Hospital Antwerp, Edegem Belgium.
gross and/or microscopic findings)
4.3.1.3.3 Lymphatic vessel invasion
4.3.1.3.4 Blood vessel invasion
ate)
4.3.1.3.5 Perineural invasion
4.3.1.3.6 Periprostatic tissue invasion (if appropri-
DIAGNOSIS AND STAGING WORKGROUP
Overview
4.3.1.3.7 Direct extension to adjacent organs(s):
specify
4.3.1.3.8 Seminal vesicle(s) invasion
4.3.1.4 Status of margins, if possible
4.3.1.5 UICC/AJCC pT category
4.3.2 Malignancy indeterminate (specify nature of 
the problem)
4.3.3 No tumor identified
4.3.4 Other findings, as appropriate
4.3.4.1 PIN and grade
4.3.4.2 AAH
4.3.4.3 Prostatitis (granulomatous or other)
4.3.4.4 Benign prostatic hyperplasia
4.3.4.5 Basal cell hyperplasia
4.3.4.6 Postatrophy hyperplasia
4.3.4.7 Therapy related 
4.3.5 Lymph node examination
4.3.5.1 Total number of lymph nodes examined
4.3.5.2 Number with metastases
4.3.5.3 Size of largest metastasis
4.3.5.4 AJCC pN classification
4.4 Special studies designate special studies, if
done, and include results with Surgical Pathology Con- Digital rectal Examination (DRE) is a simple, inexpen- 
sultation Report (e.g., histochemistry, immunohisto- sive, and direct method of assessing the prostate. When
The group considered that:
1. The objective of screening for prostate cancer is the 
detection of clinically significant tumors that are 
potentially curable in patients who have a life ex­
pectancy of at least 10 years postscreening and are 
otherwise candidates for therapy.
2. Methods of screening are limited with regard to 
sensitivity and specificity and there is as yet no con­
sensus on normal ranges of serum prostate specific 
antigen (PSA) in relation to prostate volume, PSA 
density, and patient's age.
3. Staging systems need flexibility to incorporate new 
technology and to reflect the histologic potential of 
cancers discovered by screening. Clinical staging 
falls short of pathologic staging because of limita­
tions of current technology.
Digital Rectal Examination
chemistry, flow cytometry, nuclear morphometry)].
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undertaken by a trained health care professional, the 
positive predictive value can be 25-50%.1 Experience 
from Sweden indicated that it may be feasible to train 
nonphysicians to evaluate the prostate sensitively and 
effectively, but it was agreed that such a practice may 
be unacceptable in certain cultures. It was agreed that 
universal training of medical students to carry out DRE 
should be a goal of medical education. However, it must
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not be forgotten that the finer interpretation of the re­
sults of DRE is best undertaken by a trained urologist, 
even though it is accepted that DRE is a subjective pro­
cess that has limited value for diagnosis and staging, 
DRE, as a simple procedure, is inadequate for diagnosis 
and screening and inaccurate for staging.2,3
Tumor Markers
Prostate Acid Phosphatase
It was agreed that prostate acid phosphatase may have 
limited use in staging but not in diagnosis or screening. 
An elevated PAP is indicative of local or metastatic 
spread of prostate cancer and usually indicates noncur- 
able disease,4
Prostate Specific Antigen
It was agreed that PSA is the most appropriate tumor 
marker to screen for prostate cancer but has limited ac­
curacy in staging.5-7 There was no argument about the 
absolute upper value of normality (4 ng/m l mono­
clonal); in Europe, prostate volume is considered to be 
important, but it was agreed that this is an important 
priority for the future. Data were presented that indi­
cated that PSA generally is proportional to prostate 
(and tumor) volume, and that a PSA greater than 6 ng / 
ml is more commonly associated with a tumor volume 
that may not be curable.8,9 Bostwick et al.'s data indi­
cated that a tumor volume of 5 cc had a 10% chance of 
positive lymph nodes, whereas others have shown up 
to a 21% incidence of metastases in tumors with a vol­
ume of 4-16 cc (Fig. I).9
The issue of the significance of PSA detected tu­
mors should be addressed in designing screening trials,
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Figure 1. Relationship of tumor volume and PSA. Assuming a 5 cc. 
tumor volume is the upper limit of organ confined disease, the 
shaded area denotes the PSA range of maximum curability.
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Figure 2, Comparison of T stage of radical prostatectomy specimens, 
controlled for PSA level, in PSA detected (DRE negative) vs. 
abnormal DRE. There is no significant difference in either group 
stratified for PSA.'
because the intent is to impact only those tumors that 
are biologically significant. Data were presented indi­
cating that tumors detected with a serum PSA of 4-10 
ng/m l are associated with a 30-50% incidence of cap­
sular involvement and up to 10% incidence of seminal 
vesicle involvement (Fig. 2).10,11 All accepted that longi­
tudinal PSA measurements are very promising for fu­
ture study in screening, particularly when PSA is less 
than 10 ng/ml.
Quality assurance of PSA assay is crucial for screen­
ing programs and it was agreed that this should be per­
formed in Central Reference Laboratories. Also, PSA 
has a practical advantage over PAP in that it is stable 
at room temperature and therefore is suitable for batch 
processing and off-site collection (Dr. A. Lijia, personal 
communication). Caution was urged for some instances 
of mildly elevated PSA that increase due to infection
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(prostatitis) and a consideration should be made for trial 
of antibiotics.
Transrectal Ultrasound
Transrectal ultrasound of the prostate is now generally 
reserved for the evaluation of abnormal DRE or PSA 
elevated beyond 4.0 ng /m l.12“14 This helps select for 
higher risk patients and increases the predictive value 
for transrectal ultrasound abnormalities. Transrectal ul­
trasound appearance of prostate cancer follows the gen­
eral morphologic breakdown of: 30% nodular, 50% 
nodular and infiltrative and 20% infiltrative.15 This cor­
responds to a spectrum of very hypoechoic to isoechoic 
appearance, respectively. Both the anterior and poste­
rior periphery of the prostate should be searched care­
fully for lesions 6 mm-2 cm in diameter, corresponding 
to approximate tumor volumes of 0.2 cc-5.0 cc. This 
leads to optimal localization of pathologically confined 
cancer for diagnosis. A volume obtained by height, 
width, and length measurements also provides correla­
tion with PSA.16
Staging
The confirmation of transrectal ultrasound abnormali­
ties have been simplified by transrectal automated 18 
gauge biopsy. As cancers enlarge, their margins may be­
come more ill-defined yet also cause adjacent architec­
tural distortions by mass effect. Capsular bulging, espe­
cially near the periphery, should prompt closer evalua­
tion of potential extracapsular extensions. Biopsy of 
extracapsular extension or adjacent seminal vesicles 
could produce histologic confirmation, not afforded by 
other staging modalities. The estimated tumor volume, 
or gland involvement, has also been suggested by the 
number of involved cores if systematic biopsy is per­
formed.17 Systematic biopsy may increase cancer yield, 
especially in patients with disproportionate PSA eleva­
tions (e.g. serum PSA > gland vol X 0.1 ng /m l/ cc). PSA 
density also correlates with increasing probability for 
extracapsular extension.16,18
Pelvic Lymph Node Dissection
The committee noted that while pelvic lymph node dis­
section provided the most accurate means of assessing 
the pelvic lymph nodes, that it was not curative and the 
recurrence rates reported ranged from 23 to 30%. 19~21 
There is a group of patients in whom pelvic lymph node 
dissection may be of limited benefit as the current inci­
dence of positive nodes is <5%.
Computed Tomography Scan Magnetic 
Resonance Imaging
Computed tomography scan magnetic resonance im­
aging was agreed to provide limited usefulness in stag­
ing.
Cystoscopy
It was agreed that cytoscopy provides no usefulness in 
staging.
Radionuclide Bone Scan
Radionuclide bone scan is useful in assessing the bony 
extent of metastases. It is, however, rarely positive in 
patients with a serum PSA less than 20 ng/ml. In the 
absence of an elevated alkaline phosphatase or symp­
toms, it could be omitted in patients with clinically lo­
calized cancer, a serum PSA less than 20 ng/ml, and
well to moderately differentiated (Gleason 2-7) can-
22cer.
Pathologic Predictors
In addition to the above-mentioned staging techniques, 
there are certain pathologic predictors of stage, includ­
ing Gleason sum and tumor volume, that should be in­
corporated into the staging algorithm.
Conclusions
The committees agreed that screening may provide a 
significant impact upon the natural history of prostatic 
adenocarcinoma, but that the parameters should be 
well defined. Patients who undergo screening should 
do so only if they are expected to benefit from the alter­
ation in therapy. This would include those men 1) in 
whom prostatic cancer is likely (over the age of 40 or 
50), 2) who have an expectation of survival of 10 years 
or longer and, 3) who are otherwise candidates for ther­
apy. There are current guidelines by the American Uro- 
logic Association and American Cancer Society as to 
when screening should begin, but these organizations 
specify no upper limits of age or health at which time 
screening becomes of little value.
The groups further agreed that the methodology for 
screening should be a combination of PSA and digital 
rectal examination. Transrectal ultrasound was felt to 
be a useful adjunct in the event of an abnormal exami­
nation. The frequency of examination was discussed, 
and although the general feeling was that annual exam­
inations are optimal, there were no data presented to
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support this stance. The level of " abnormal" PSA 
should be sufficiently low to allow optimal detection in 
terms of both numbers of significant tumors and curable 
tumors (defined as tumors confined to the prostate). 
This would correlate with a "window of opportunity" 
between a serum PSA of 2 and 6 ng/m l. Age-specific 
ranges were discussed and felt to be another attempt to 
increase the specificity and sensitivity of PSA, yet per­
sonal data of LaBrie refuted age-specific PSA.23
Staging systems were discussed and it was felt that 
because the stage was a reflection of the biologic hazard 
of the disease, the palpability of a lesion was a poor 
marker, as a large number of tumors were anterior or 
hidden in a large adenomatous gland. The best predic­
tor of biologic hazard is the volume of the tumor, yet 
there currently is no technology available to accurately 
assess the volume preoperatively.
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LABORATORY EVALUATION WORKGROUP
It is now well established that the determination of the 
concentration of prostate specific antigen (PSA) in se­
rum is of clinical value in monitoring the treatment of 
patients with prostatic cancer.1 Moreover, there is now 
good evidence2 that the determination of serum PSA 
levels will make a significant contribution to the new 
screening initiatives directed to the recognition of early 
prostate cancer, Such screening studies are currently the 
center of considerable controversy,3 although a number 
of case control studies have established the potential of 
the serum PSA analysis and digital rectal examination 
as the currently available primary tests to identify early, 
probably organ-confined prostatic cancer. Transrectal 
ultrasonography is generally seen as the secondary pro­
cedure to be undertaken if either of the primary tests is 
positive.
Randomized screening studies are necessary to de­
termine whether the use of such tests is appropriate and 
when used in populations of asymptomatic normal 
men, will reduce the mortality from prostate cancer. A 
range of serum PSA concentrations from 0 to 4.0 ng/m l 
has been seen for some time by the international uro­
logic community as normal. Levels of serum PSA 
greater than 4.0 ng/m l therefore would be viewed with 
some suspicion with regard to the possibility of cancer, 
In a population of normal men older than 55 years, 2 
to 3% would be expected to have levels of serum PSA 
greater than 10.0 ng/m l and about 10% would be in the 
4.0-10.0 ng/m l range. Avalué of 10,0 ng/m l or greater 
should require serious clinical evaluation, with a large 
proportion of such subjects expected to have dissemi­
nated disease. On the basis of such studies, the Ameri­
can Cancer Society has recommended an annual digital 
rectal examination and PSA analysis for all men over 
the age of 50.
The arbitrary PSA value of 4,0 ng /m  as a cutoff 
point for cancer dominated discussion related to screen­
ing for the last 5 years, with studies indicating that 
many men in the 4.0 to 10 ng/m l range have cancer 
confined to the prostate, Considerable emphasis is di­
rected to the potential value of PSA analysis for the rec­
ognition of early cancer. Laboratory specialists have in­
dicated, however, that PSA immunoassays can only 
provide a guideline as to the level of PSA in serum.4 
There is no internationally recognized PSA standard 
reference material against which the calibration of such 
immunoassays for PSA measurement can be validated. 
There is, moreover, no recognized procedure that
would readily be accepted as the "definitive" assay. 
Different studies have shown the various immunoassay 
kits for the measurement of PSA, produced by a num­
ber of diagnostic companies, provided widely varying 
results from the same serum sample.
The consensus committee discussed the biochemis­
try relating to the production of PSA by the epithelial 
cells of the prostate. It is recognized5 that the PSA mol­
ecule was essentially of the kallikrein family and as a 
serine proteinase, has the capacity to bind in the serum 
to the proteinase inhibitors «i-antichymotrypsin and 
a 2-macroglobulin.6 A major proportion (65-90%) of the 
PSA that is measured by PSA immunoassays is in the 
form of the PSA-c^-antichymotrypsin complex. The 
PSA that is complexed with a:2-macroglobulin is not 
recognized by the antibodies currently used as compo­
nents of any diagnostic PSA immunoassay kit.6"8
The PSA immunoassay kits therefore measure PSA 
that is in the free, unbound state, and also the PSA that 
is complexed to -«i-antichymotrypsin. The sum of both 
indices provides the "total PSA" level in serum,7 De­
pending on the antibody composition of the various 
kits, the total PSA value will vary according to whether 
the free PSA and complexed PSA are determined on 
an equimolar basis.9 The experimental data suggest that 
few commercially available assays can measure free 
and complexed PSA in an almost equimolar equiva­
lence pattern. The level of total PSA in serum, measured 
by procedures that determine the free and the com­
plexed PSA on an equimolar basis, would be consid­
ered, at present, to provide the most likely accurate 
value. The Hybritech Tandem R assay was recognized 
by the committee as an acceptable provisional reference 
method. Many other kits do not appear to measure se­
rum PSA components in this equimolar manner. The 
committee considered, therefore, that the varying levels 
obtained with different kits is a problem that could well 
relate to the capacity of the immunoassay under the 
specified analytical conditions, to measure free and 
complexed PSA.
Information was made available to the committee 
to indicate that when specific assays were established to 
separately determine the concentration of free PSA as 
well as the levels of PSA complexed to a r antichymo- 
trypsin, the ratios of free PSA/total serum PSA, or of 
PSA-^-antichymotrypsin complex/total serum PSA, 
appear to provide sensitive parameters that would al­
low a more specific differentiation of patients with be­
nign prostatic hyperplasia from those with cancer in the 
screening programs.8,10,11 Such assays could reduce the 
false positive rate by about 50%.10 It was noted by the 
committee, however, that these assays are not yet avail­
able for current screening studies.
The committee considered that it should be prag­
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matic about the "laboratory requirements" necessary 
for the support of the screening studies and recom­
mended that a short term and a longer term program 
should be established. The long term goal is to establish 
international PSA standard preparations, but in the 
short term, it will be necessary to prepare a provisional 
PSA standard that would be available for the Pan-Eu­
ropean Screening Program.
Such a standard could be obtained as follows. First, 
samples of PSA isolated from seminal plasma should be 
obtained from sources that could provide evidence of 
acceptable purity and characterization. A PSA concen­
tration would then be assigned to the preparation of 
PSA in buffer medium, by use of "the provisional refer­
ence assay." Samples would then be aliquoted into 
tubes for stability experiments, storing samples at vary­
ing temperatures, from 0°C down to minus 70°C, as a 
preliminary study to establish conditions for the storage 
of the European reference materials. A series of labora­
tories involved with the screening studies would per­
form the analytical work to assign the PSA concentra­
tion to the standard preparation. Furthermore, a series 
of "pools" of serum would be prepared containing lev­
els of PSA in the range between 0 to 10 ng/ml. These 
pools would form the basis of a quality assurance pro­
gram to monitor the performance of the laboratories in­
volved in the determination of serum PSA for the 
screening studies. Randomly selected samples of 
different pools would be dispatched from a designated 
center to the laboratories at regular intervals and results 
reported to the quality assessment coordinator.
The committee also accepted that the laboratories 
would probably require an automated analytical system 
for the determination of PSA. Although the correlation 
was seen10 to be excellent, but with a small negative 
bias, between data generated by the current Abbot IMX 
automated assay and the Hybritech Tandem R proce­
dure from the analysis of a series of serum samples, ev­
idence provided to the committee indicated that there 
may still be differences between the assays as to how 
well they measure the free PSA and complexed PSA 
on a molar equivalent basis. Such differences could be 
readily overcome by the selection of appropriate anti­
bodies that can provide equivalence in the detection of 
different molecular forms of PSA in automated assay 
systems, although these may not yet be commercially 
available. It was recommended that if possible, all the 
laboratories concerned in the screening studies would 
use an automated assay.
Once evidence that other immunoassay systems 
were able to provide analytical equivalence and satis­
factory precision, as documented by the quality assur­
ance program, then they should be considered for use 
in the screening studies.
In the longer term, the application to the European 
Community for financial support for the cooperating 
laboratories to produce European reference materials 
containing PSA and PSA-c^-antichymotrypsin com­
plex would be submitted on April 14, 1994, the next 
acceptable date for such requests. Standardized isola­
tion and characterization procedures would be estab­
lished and such materials would be processed according 
to the standards of the European Community Bureau of 
Reference Materials, to produce the European standard 
preparations of both PSA and PSA-complex that could 
then be used for assay validation. It would be expected 
that diagnostic kits for total serum PSA analysis would 
determine the different molecular forms of PSA at mo­
lar equivalence. The complexed PSA would be made 
available for the development, establishment, and vali­
dation of the next generation of more specific assays for 
the determination of the free PSA, and the PSA-a^-an- 
tichy mo trypsin complex in serum. The European stan­
dard preparations would then be made available and 
distributed through the World Health Organization, if 
this was considered appropriate.
Although new markers for prostatic cancer will in­
evitably be developed for future years, a shorter-term 
goal is to establish the more specific assays for the mea­
surement of the various molecular forms of PSA. At 
present, the determination of "total PSA" levels in se­
rum provides the only practical and rational means 
available for the identification of early prostate cancer. 
These assays must be better monitored in the screening 
studies and assay precision established for the lower 0 
to 10 ng/m l range to determine, more accurately, the 
relevance of the "cancer cut-off point," be it 3.0 or 4.0 
ng PSA/ml serum.
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TREATMENT WORKGROUP 
Introduction
Localized prostate cancer represents a disease spectrum 
of clinical stages from Tla to T3. Within each stage exist 
variations in malignant potential. Several clinical, bio­
chemical, and radiographic factors are considered in the 
assessment of the individual T stage, including digital 
rectal examination, transrectal ultrasound, prostate spe­
cific antigen (PSA), PSA density, magnetic resonance 
imaging, tumor grade, ploidy, and lymph node status. 
For example, category T3 includes both patients with 
minimal capsular penetration (as identified by digital
rectal examination, transrectal ultrasound, or even nee­
dle biopsy) as well as patients who have bulky T3 tu­
mors with symptoms of an obstructive nature. Some of 
the former may still be localized and curable, whereas 
the majority of the latter will have nodal metastases. 
Despite the importance of T-staging, in some surgical 
series only 22% of patients have been staged accu­
rately.1,2
The concept of "localized disease" implies that it is 
curable, with acceptable treatment mortality. There­
fore, for the purpose of this workshop discussion, our 
definition encompasses a range of prognostic criteria 
that, for an individual patient, are considered to be syn­
onymous with curability. Many parameters are used to 
assess curability; for example, a poorly differentiated 
Gleason sum grade 10 T2 cancer is not likely to be cured, 
whereas a well differentiated Gleason grade 4 tumor is.
We are witnessing both a stage and intrastage mi­
gration in prostate cancer toward more favorable prog­
nostic groups. This phenomenon may influence treat­
ment selection and must be recognized when at­
tempting to compare current treatment strategies with 
past experience.
The presence or absence of lymph node metastasis 
is an important prognostic factor. When considering 
treatment for localized disease, lymph node status 
should be ascertained with reasonable certainty. De­
spite this, many patients do not undergo lymph nodal 
assessment. In general, a relationship exists between tu­
mor (Gleason) grade, PSA, and lymph node status.1,3,4 
(Tables 1 and 2) Patients with a PSA less than 20 ng/ml 
and a Gleason grade less than 7 have a low risk of
Table 1. Risk of Lymph Node Metastases Versus 
Gleason Grade
Percent node positive
Gleason sum P artin * W o lff  Kleer$
1
* 14
✓
5
6 
7
Overall percent node positive 
Total no. patients
* Jou rnal of Urology 1993;150:110-4. 
t  Journal of Urology 1993;42:131-7.
$ Journal of Urology 1993;41:207-16.
1 0
8
4
8
20
42
11
703
21
10
164
26
13
975
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Table 2. Risk of Lymph No de Métastasés Versus 
Preoperative Sérum Prostate Specific Antigen
Percent node positive
PSA ng/ml P art in * W o//t KleerX
0-4 1 8 3
4-10 12 ] 5 6
10-20 18 J
►
16 (10-25 ng/m l)
20-30 26 - 1 ----------
30-40 42 > 31 ^ 25 (25-50 ng/m l)
40-50 25
*
>50 74 ---------- 52
Overall percent node 
positive 11 10 13
Total no. patients 703 164 975
* Journal of Urology 1993;150:110-4. 
t  Journal of Urology 1993;42:131-7. 
 ^Journal of Urology 1993;41:207-16.
lymph nodal metastases, However, a poorly differen­
tiated (Gleason sum 8) with PSA of 15 ng/m l may have 
a 20% risk of nodal disease. The goal of any treatment 
for localized prostate cancer is to improve patient sur­
vival while preserving the best quality of life. In other 
words, giving the patient "the best chance of dying of 
something else/' Thus, treatment should be considered 
for any man with prostate cancer whose survival, in the 
opinion of the clinician, will be shortened by the cancer. 
Usually, these are men with a life expectancy greater 
than 10 years and whose treatment would be expected 
to influence outcome. In this decade, economic issues as 
well as therapeutic efficacy are influencing such treat­
ment decisions. Economically, curative treatment of 
early disease may be more attractive than treating ad­
vanced disease. However, it is not known what strategy 
is ethically and economically desirable.
Treatment Options
Having defined localized prostate cancer and whom to 
treat, we review the options available for treatment. The 
choice of therapy depends upon the T stage and, as pre­
viously discussed, the overall health of the patient. 
Watchful waiting may be very appropriate for an 
asymptomatic patient with a Tin cancer whereas a high 
grade, Gleason 9 T3 cancer may benefit from radiation 
therapy, even though the likelihood of cure could be 
remote. Treatment options should be discussed with the 
patient and in some cases second opinions sought from 
multiple specialties.
Treatment options for localized prostate cancer 
have been embraced with varying degrees of enthusi­
asm. Opinions and practices have changed considera­
bly over the past decade. The list of therapeutic options 
includes time-honored methods of radical prostatec­
tomy or radiation therapy as well as watchful waiting, 
br achy therapy, hormone manipulation, and cryother­
apy. The major challenge facing the clinician regarding 
treatment options is the lack of data from randomized 
clinical trials.
Radical Prostatectomy
Radical prostatectomy is the gold standard for the treat­
ment of localized prostate cancer. Through the early 
1960s, the perineal surgical approach was the only cu­
rative procedure for highly selected patients with small 
nodules. As a result of greater understanding of the rel­
evant anatomy and the refinement of the nerve-sparing 
retropubic radical prostatectomy, the complications of 
surgical treatment have decreased significantly.
The most important and significant early complica­
tion is postoperative mortality. In the age and health 
group of a screened population, the expected mortality 
in major centers will be approximately 1% (±0.9%) 
within 30 days and 1,2% within four months.5"7 In 
some urologie practices, mortality rates are higher. A 
second early complication is rectal injury, with a re­
ported frequency of approximately 3%.8 This complica­
tion, however, has little long term importance. Stric­
tures, incontinence, and impotence are the major late 
complications. None influence survival but all definitely 
affect quality of life. Stricture frequency is about 20% 
and relatively easy to handle. Incontinence and impo­
tence are also age- and stage-related. Overall final in­
continence rates should be less than 5%, although this 
is certainly a question of definition. Impotence is a ma­
jor quality of life issue, but its frequency has decreased 
considerably with the adoption of nerve-sparing surgi­
cal techniques.7 Treatment of incontinence and impo­
tence can have considerable cost implications. These 
should be taken into account when performing finan­
cial cost-benefit analysis of screening programs.8
Perhaps for more than any other treatment mod­
ality, the outcome of radical prostatectomy is inextrica­
bly related to pathologic stage. If the malignancy is or- 
gan-confined, long term survival is indistinguishable 
from age-matched men without prostate cancer.1,6 Fif­
teen-year survival rates in excess of 50% have been re­
ported. The survival of men with locally advanced (T3 
or T4) disease is considerably less.
The postoperative follow-up of men treated with 
radical prostatectomy has been revolutionized by the 
advent of assays for the detection of serum PSA. Mea­
surable levels of PSA after radical prostatectomy are a 
harbinger of clinically evident persistence disease, al­
though the prognostic value of this biochemical marker
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is unknown with respect to individual morbidity or can­
cer-specific mortality. The impact of adjuvant therapy 
on incomplete surgical resection or postoperatively de­
tectable serum PSA is unknown. Several trials have 
been initiated to study these issues. At the present time, 
there is insufficient data to support the use of postoper­
ative hormone therapy as an adjuvant in the treatment 
of localized prostate cancer except in the context of clin­
ical trials.
Neoadjuvant Hormone Therapy
Several studies are in progress evaluating neoadjuvant 
hormone ablation before radical prostatectomy or radi­
ation therapy.2,9"11 Labrie and others2 demonstrated a 
significant reduction of positive margins in men receiv­
ing three months of an antiandrogen plus luteinizing 
hormone-releasing hormone agonist before radical 
prostatectomy compared with men undergoing imme­
diate surgery without hormone therapy. Similarly, the 
Canadian Anadron Trial and the Radiation Therapy 
Oncology Group have reported significant decrease in 
local recurrence and improvement in disease free sur­
vival in men with T3 prostate cancer receiving neoadju­
vant hormone ablation.11
Cryotherapy
There has been a resurgence of interest in cryoablation 
owing to improved delivery systems and, particularly, 
to the ability to visualize tissue freezing by transrectal 
ultrasound. These factors have contributed to a signifi­
cant reduction in morbidity. Long term outcome data 
are lacking, but in one recent series, 62% of men had 
negative biopsy at three months.12 The ability to freeze 
beyond to the prostate capsule makes this modality ap­
pealing for some patients with clinical stage T3 disease. 
In addition, this approach holds promise for some pa­
tients failing primary radiotherapy,
Morbidity does occur with this method of treat­
ment. Rectal fistula, sloughing of urethral tissue, impo­
tence, penile edema, and voiding difficulty have all 
been reported,12 Long term follow-up of patients un­
dergoing cryoablation will be required before the effi­
cacy and morbidity of this procedure can be deter­
mined. At the present time, this treatment should only 
be used in the context of a clinical trial.
Radiotherapy
Radical external beam radiotherapy has become possi­
ble with the development of high energy radiation 
equipment, earlier with cobalt 60 treatment units and
with linear accelerators beginning in the 1960s. The 
pattern of care study (PCS)13 reported radiotherapy 
treatment results for localized prostate cancer from a 
large number of research and nonresearch centers. The 
aim of this review was to produce data that were un­
likely to be biased by any single institution. Sixteen- 
year overall survival of TtN0 patients was similar to a 
healthy age-matched population. Survival of T2NP was 
22% lower than the age-matched controls. Survival of 
T3/T 4Nq was about 15% lower than T2N0 at 10 years 
but was identical at 16 years. Other single institution 
series report essentially similar results.14,15 Pooled data 
from the literature report 0.2% fatal complications after 
radiotherapy. The overall incidence of significant uri­
nary or rectosigmoid sequelae is approximately 3% and 
7-10% for severe and moderate complications, respec­
tively. The most frequent urinary sequelae are radiation 
cystitis with intermittent hematuria and urethral stric­
tures. The incidence of severe anal/rectal injury requir­
ing colostomy is less than 1%. These complications are 
related to treatment technique. A sexual dysfunction 
has been described in 14 to 50% for patients depending 
upon age, time of assessment, and technique of irradia­
tion. However, prospective data comparing postradio­
therapy impotence with the natural evolution of sexual 
dysfunction are presently lacking.14
Progress in radiation computer technology (either 
with conventional radiation or proton beams) and im­
aging as well as in the physics of radiation have modi­
fied the practice of radiotherapy considerably, Emerg­
ing data for three-dimensional conformal radiotherapy 
indicate that higher doses can be delivered safely to the 
prostate gland without increasing treatment morbid­
ity.16,17 This observation assumes particular importance 
in view of the strong relationship existing between ra­
diation dose, local control, and survival.15 The same ra­
tionale supports the renewed interest in prostate cancer 
brachytherapy18 although the consensus of this work­
shop is that the technical difficulties of brachytherapy 
may limit its role and make it less attractive than 3-D 
conformal radiotherapy. Long term data on local con­
trol and survival of localized prostate cancer with these 
sophisticated modern imaging therapies are not yet 
available.
Recent data indicate that pretreatment PSA levels, 
when considered together with clinical stage and grade, 
will help to define patient subgroups with different 
probabilities of local control and disease free survival 
after radiotherapy. Poor prognostic groups on which to 
focus clinical trials that employ more intensive local 
treatment or adjuvant systemic therapy including hor­
mones can be identified by these means. There are also 
indications that postradiotherapy PSA levels will help 
to identify at an early stage those patients who are likely
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to relapse and who should be considered for salvage 
therapy.19,20
Treatment of Tumor Relapse
Many men treated for localized prostate cancer will 
demonstrate local recurrence despite the curative intent 
of the treatment. Recurrence may be identified by sev­
eral parameters, including palpable local recurrence, 
positive biopsy, detectable serum PSA after radical 
prostatectomy, or rising PSA after achieving a nadir in 
men treated with other modalities. The therapeutic op­
tions for tumor relapse are predicated on the primary 
therapy administered. Radiation therapy may be 
offered to a patient who develops local relapse after 
radical prostatectomy. The benefit of such treatment is 
presently unknown. Salvage prostatectomy after radio­
therapy failure is feasible but rarely successful. Hor­
mone therapy is usually effective in altering biochemi­
cal markers (PSA); however, its impact on altering sur­
vival is unknown. Recently, cryotherapy has been 
suggested as an alternative for patients failing radiation.
Watchful Waiting
Several studies have provided long term follow-up for 
watchful waiting of localized prostate cancer indicating 
a favorable outcome.21“24 These studies have been criti­
cized for various biases, but their overall conclusion 
should not be ignored. For many patients with signifi­
cant comorbidity, watchful waiting may be appropriate 
because the probability of noncancer death could be 
high.
The question that remains is whether watchful 
waiting is equivalent to immediate treatment for 
healthy patients with a long life expectancy. Four im­
portant factors raised by these studies need to be con­
sidered:
Death from Prostate Cancer
These studies reported that death from prostate cancer 
within 10 years was 7 to 8.5%, compared with 31 to 
47% from other causes. Longer follow-up data are lack­
ing, This survival differential may change, suggesting 
that the present data should be applied to younger men 
with caution,
Progression
In most patients, once progression has been observed, 
cure is no longer possible. One exception is that pro­
gression from Tlc to T2 may still be curable. Local pro­
gression to T3 occurred in 22 to 55% of patients, but this 
causes concern to the physician more frequently than 
the patient. Patients who need treatment for local pro­
gression are usually few. Distant metastases developed 
in 12 to 14 % during watchful waiting. At this time treat­
ment can only be palliative.
Quality of Life
Assessment of quality of life in patients with localized 
prostate cancer must be evaluated in terms of "health" 
rather than "disease/' Although the review by Fleming 
and others23 was based on such a conception, it did not 
address the patient's own perception of living with can­
cer.
T reatment Decisions
Watchful waiting implies treatment for progression. If 
palliative treatment only is planned, it may be argued 
that follow-up is not necessary. However, if immediate 
treatment is considered necessary at the time of pro­
gression, therapy will depend upon the type of progres­
sion. Should a rising PSA be treated? If so, at what PSA 
level? Furthermore, what constitutes "local progres­
sion?"
Summary
There are advantages and disadvantages to each of the 
treatment modalities available for localized prostate 
cancer. For individual patients, treatment selection 
should consider all these factors in concert with the pa­
tient's acceptance of the side effects and the expected 
results of each treatment choice.
Readers should note the absence of a table compar­
ing the outcome of different treatments, This is not an 
oversight but illustrates the workshop view that ade­
quate randomized trials of treatment for localized pros­
tate cancer have not been performed and that data de­
riving from different treatment modalities are not com­
parable. The most pressing issue for the treatment of 
localized prostate cancer is the development of reliable 
prognostic markers that will allow the separation of 
those men who will die of prostate cancer from those 
who will not. Thereafter, the impact of intervention 
must be determined.
Meanwhile, the organization of prospective trials is 
necessary if informed decisions are to be made in the 
future. In designing such trials, the endpoints must be 
identified clearly and must include overall survival, 
time to progression, and quality of life. For this purpose, 
the assessment of comparative treatment morbidity re­
quires refinement for use in clinical trials.
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Constant monitoring will be needed, and evalua­
tion analysis must consider not only the trial itself but 
also any progress in developing therapeutic methods.
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TRIAL ORGANIZATION WORKGROUP
The committee on trial organization agreed that at this 
time there is insufficient evidence of potential benefit to 
support the use of widespread population screening 
tests for prostate cancer outside of research studies. 
Meanwhile, there are different criteria upon which to 
base evaluations of screening programs, depending on 
the objectives to be achieved; for example, demonstra­
tion projects for feasibility purposes or randomized con­
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trolled trials for effectiveness evaluation. The commit­
tee mainly considered questions related to the latter.
What Is the Most Appropriate Design to Study 
the Effectiveness of Prostate Cancer Screening?
The design must avoid biases caused by selection, lead 
time, and length. This can be best achieved by a con­
trolled trial in which an identified study population of 
sufficient size is randomized into two arms. One is 
offered screening tests, and the other receives routine 
health care. Both arms are to be followed up from the 
date of randomization and total prostate cancer mortal­
ity recorded. Analysis must be on an "intention to treat" 
basis.1 Within this basic framework, randomization 
may precede consent (the target population is the same 
as the study population) or follow consent (the study 
population is smaller than the target population). If 
there are ethical objections because the control arm re­
ceives no potential benefit, then it would be possible to 
offer screening to the control group after a delay of sev­
eral years,2,3
Lessons from breast cancer screening trials show 
that individual randomization is to be preferred.4
Details Concerning Randomized Controlled 
Screening Trials
Age Range
The selection of the age group is influenced by the inci­
dence rates and by life expectancy.5 Therefore the com­
mittee recommended selecting a target group ages 55 to 
70 years at entry to the trial. There are no good argu­
ments for starting screening under the age of 50. Al­
though some individual men between the ages of 50 to 
54 years might have most benefit in terms of years of 
life gained, the costs for each additional year will be 
extremely high.
Interscreening Interval
Recent results from the Canadian6 and the US ACS- 
NCDCP7 demonstration screening projects show inter­
esting results based on annual prostate specific antigen 
(PSA) tests, obtaining detection rates of greater than 
2.0% to 3.0% after 1, 2, and 3 years screening. Con­
versely, this short time period may not provide enough 
relevant data on interval cancer cases to investigate the 
natural history of the disease under study. In addition, 
annual screening may be less likely to be cost-effective 
and could probably result in high costs per additional 
cancer case detected. Therefore the majority of the com­
mittee recommended a rescreening period of at least 3 
years for randomized controlled trials. Supporting this 
design are the recent results from the Canadian project.6 
Reports from the American Cancer Society Project in 
the USA support the cost-effectiveness of annual 
screening.7,8
Screening Tests
Despite evidence that PSA, or PSA combined with 
DRE, as primary screening tests, could be an effective 
choice, the use of the 3 screening tests (digital rectal ex­
amination, PSA, and TRUS) is recommended at the 
start of the European trial.8-10 At present time there is 
not enough information available from the European 
pilot studies to delete one of them as being of poor cost- 
effectiveness for the detection of early cancer cases 
when a rescreening interval of more than 3 years is pro­
posed. For scientific purposes it is recommended that 
serum samples are taken from each individual and 
stored. Strict objective criteria that could be easily ap­
plied should be defined for the selection of suspected 
cases on DRE and TRUS. Biopsy should be taken from 
patients with suspected cases as agreed by the diagnos­
tic and laboratory committees.
Outcome Measures
The primary outcome measure of the trial will be pros­
tate cancer mortality reduction. Quality of life measure­
ments and cost parameters must also be included as in­
trinsic components of this trial design. To measure cost- 
effectiveness of different screening strategies and costs 
per prostate cancer death avoided, it is recommended 
that resource use in both arms is recorded. The data can 
be collected for the total group or in a subsample of in­
dividuals.
Whether analyzing duration of survival, quality of 
life, or cost parameters, all measurements should be 
stratified retrospectively for important prognostic fac­
tors, such as advanced disease.
What about Recruitment?
European pilot studies in Rotterdam and Antwerp show 
that between 36 and 42% of men from the target popu­
lation are willing to join the study population of ran­
domized screening trial. Fortunately, screening trials 
with low rates of recruitment could yield unbiased re­
sults so long as randomization is applied after recruit­
ment. High compliance rates within both arms of this 
study population will increase statistical power. Possi­
ble specific ways to increase those rates could be the use
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of professional media techniques and personal mail­
ings.1 Generalization of the results to the target popula­
tion will be more straightforward if high recruitment 
rates have been achieved (or if the study population is 
representative of the target population). However, pro­
motion of screening is very complex because it may en­
hance contamination of the control arm by the use of 
screening tests. In screening demonstration projects 
such as conducted in the US, (ACS-NPCDP)7 higher re­
cruitment rates may be achieved because the message 
to the population promises potential benefits. This is 
difficult to promote in the context of a randomized con­
trolled trial.
Is Overdiagnosis a Concern?
The term "overdiagnosis" refers to the possibility that 
screening detects excess numbers of small volume (0.05 
to 1.00 ml) tumors. Evidence is accumulating in the lit­
erature that PSA screening, even when accompanied by 
an aggressive biopsy policy, does not lead to overdi­
agnosis in this sense.11,12 Overdiagnosis can also be in­
terpreted as detection and treatment of tumors which, 
although classified as biologically important, would not 
have become life threatening. Epidemiologic data on in­
cidence and mortality of prostate cancer, particularly 
from the US, show that despite a tremendous incidence 
increase during the last decade, mortality has remained 
relatively constant.13 This suggests that screening may 
lead to overdiagnosis in this latter sense. It could also 
mean that current screening is finding significant can­
cers, preventing an increase in mortality despite an in­
crease in incidence. It will be essential to monitor cumu­
lative incidence of prostate cancer in the two arms of 
the trial to determine whatever occurs.
Trial Committees
Several trial committees are required: the causes of 
death committee, quality control committee, and an in­
dependent data monitoring committee that will estab­
lish stopping rules, apply ethical standards to interim 
results, and if necessary, review early mortality results.
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CHAIRMEN'S SUMMARY
During this workshop we received confirmation that 
there has been a progressive rise of a significant degree 
in prostate cancer incidence in North America and 
Western Europe, for at least the last 8 years. Although 
the mortality rates are not necessarily the same in both 
regions, it appears that they have not increased greatly.
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This has been suggested to be similar to the situation in 
the 1970s when mammography and other associated 
tests were being introduced for breast cancer screening 
in the United States. There is no current basis for pro­
jecting how long the increased prostate cancer inci­
dence will be observed, nor when it might drop with 
or without a change in mortality rates. Proposed public 
health interventions, if conducted, must be evaluated 
in the presence of such features. Intervention action by 
demonstration projects or randomized trials seems de­
sirable.
The workshop presentations and discussions have 
focused rightly on the conduct of prostate detection tri­
als. Lessons from trials of other cancer sites are available 
to be learned. Quality of assessment and uniformity of 
processing are essential features of any pathologic eval­
uation. The nature and extent of the cancers detected 
are very important in these projects. The care given the 
pathologic evaluation of the tumors found can be said 
to be one of the most important features of any good 
trial. That is certainly the case in the United States.
The reports dealing with the methods and process 
of staging and diagnosis of prostate cancer emphasized 
the use of the currently available TNM system. There is 
no need for agreement as to which techniques of diag­
nosis (prostate specific antigen blood test, digital rectal 
examination, and transrectal ultrasound trials) must be 
used either primarily or secondarily. The fact that there 
are and will be differences in this feature of trial design 
will be useful in comparing the results obtained in the 
various efforts. It is also certainly true that the cost of 
any trial can be considerable, and may have an impact 
on which diagnostic tests are chosen for primary or sec­
ondary use. We can only learn, based on the outcomes 
over time, how these features play out. There is no sure 
answer at this point.
An area of major concern is the quality assessment 
and performance of prostate specific antigen blood de­
terminations. As reported, there are differences among 
the available tests and there obviously can occur varia­
tions in test performance. Comparison of prostate spe­
cific antigen results between participating hospitals or 
institutions, variations over time, or after specimen stor­
age, present interpretation problems. There will also be 
variations between trials. These differences could be 
significant. It is hoped that by working with industry 
researchers and scientists this important concern pres­
ently can be addressed. Because detection trials are ex­
pected to obtain values from participants that are in the 
normal or near normal range, where a small variation 
might cause a significant diagnostic or therapeutic pro­
cedural change, this is a most important current con­
cern. Several of the European and North American lab­
oratories are working to provide possible solutions to
this issue, but some time will be necessary. Knowledge 
of this issue is critical for those instituting any trial, and 
should be considered by anyone conducting a current 
trial.
The trial organization for prostate cancer detection 
has and will differ, to some degree, based on whether 
the effort is a prospective randomized trial or a demon- 
stration project. Both methods provide valid and useful 
information that can be evaluated employing epidemi­
ologic and statistical techniques using other concurrent 
regional tumor registry data that can provide popula­
tion-based information on the screened or nonscreened 
population for comparisons. The types of cancers and 
other clinical features will doubtless prove to be similar 
despite differences in trial design. This feature is readily 
apparent based on the multiyear results available in the 
United States, where in the aggregate the following has 
been seen: 1) The majority of the tumors are clinically 
significant (85-90%); 2) The tumors are usually treated 
not observed; 3) The tumor size or volume, or tumor 
grades observed are comparable to those tumors being 
concurrently clinically observed or treated. It was also 
observed that small volume well differentiated tumors 
are not detected in great numbers. These clinically in­
significant tumors are generally observed and, if 
treated, they do not show poor clinical results with high 
morbidity and mortality from the treatment. The 
emerging data from multiple trials are putting to rest the 
speculations of some health economists in this regard.
Any conducted trial should be performed with the 
intention to treat those tumors found, and to do so in 
a similar fashion to those otherwise being treated. The 
treatment group reaffirmed this feature, and has pro­
vided a fair and comprehensive summary of the current 
available treatment options. This workshop has pro­
vided a very good basis for the evaluation of the current 
situation regarding the early detection and treatment of 
prostate cancer on a global basis, and we are grateful to 
the participants and the sponsoring organizations for 
their support and active participation.
The workshop goals have dealt generously and 
fairly with features of epidemiology, pathology, diag­
nosis, staging, laboratory evaluation, treatment, and 
trial organization. The reader is commended to this cur­
rent assessment of these factors as they might affect 
screening for prostate cancer.
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